STAAR SURGICAL (STAA) Upgraded by Zacks to NEUTRAL

Zacks Investment Research upgraded shares of STAAR SURGICAL (STAA) from UNDERPERFORM to NEUTRAL on November 05, 2012, with a target price of $5.20.

Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on STAAR SURGICAL (STAA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .